Skip to main content
Log in

Masking of physicians in the Growth Failure in Children with Renal Diseases Clinical Trial

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Masking — hiding identities of treatments from the patient, physician and/or statistician — is a critical element in clinical trials. Wherever possible, masking is implemented to eliminate observational bias or systematic error. In this paper, general concepts of masking in clinical trials are examined. Specific masking procedures used in the “Growth Failure in Children with Renal Diseases” (GFRD) Clinical Trial are described. A method to evaluate the “success” of this masking procedure for physicians is introduced. For each randomized patient at each clinical center, the clinic director was asked to predict which treatment (1,25-dihydroxyvitamin D3 or dihydrotachysterol) was assigned. Results showed that 72% of responses initially indicated “absolutely no idea” of treatment. Additional analyses revealed that the number and percentage of “correct” guesses were essentially equal for the two treatment groups and that a patient's time on treatment did not affect the mask. We conclude that the mask of physicians in the GFRD Clinical Trial was well maintained.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Pocock SJ (1983) Clinical trials: a practical approach. Wiley, New York, pp 90–92

    Google Scholar 

  2. Friedman LM, Furberg CD, DeMets DL (1981) Fundamentals of clinical trials. Wright, Boston, pp 59–63

    Google Scholar 

  3. Chan JCM, McEnery PT, Brouhard BH, Chinchilli VM, Greifer I (1990) History and organization of the Growth Failure in Children with Renal Diseases Study. J Pediatr 116: S3-S7

    Google Scholar 

  4. Chan JCM, Greifer I, Boineau FG, Mendoza SA, McEnery PT, Strife CF, Abitbol CA, Stapleton FB, Roy S, Strauss J (1990) Rationale of the Growth Failure in Children with Renal Diseases Study. J Pediatr 116: S11-S15

    Google Scholar 

  5. Chan JCM, McEnery PT, Chinchilli VM, Boyle RM, Massia MD, Jennings SJ, Kohaut EC, Dresner IG, Tejani A, Arbus GS (1990) Protocol of the Growth Failure in Children with Renal Diseases Study. J Pediatr 116: S17-S21

    Google Scholar 

  6. Krol WF (1983) Closing down the study. J Controlled Clin Trials 4: 505–512

    Google Scholar 

  7. SAS Institute (1990) SAS procedures guide, version 6, 3rd edn. SAS Institute, Cary, N. C.

    Google Scholar 

  8. Lipid Research Clinics Program (1984) The Lipid Research Clinics Coronary Primary Prevention Trial results: reduction in incidence of coronary heart disease. Jama 251: 351–364

    Google Scholar 

  9. Byington RP, Curb JD, Mattson ME (1985) Assessment of doubleblindness at the conclusion of the β-Blocker Heart Attack Trial. JAMA 253: 1733–1736

    Google Scholar 

  10. Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM (1975) Ascorbic acid for the common cold. JAMA 231: 1038–1042

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boyle, R.M., Chinchilli, V.M. & Shasky, D.A. Masking of physicians in the Growth Failure in Children with Renal Diseases Clinical Trial. Pediatr Nephrol 7, 204–206 (1993). https://doi.org/10.1007/BF00864403

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00864403

Key words

Navigation